Dev't of porphyria drug urged in Japan
The study Committee on the Use of Unapproved Drugs within Japan's Ministry of Health, Labor and Welfare has urged relevant drug manufacturers to rapidly develop Normosang (human hemin) for the treatment of hepatic porphyria (acute intermittent porphyria, variegate porphyria, hereditary co-proporphyria and sigma-aminolevulinate dehydratase deficiency porphyria).
Normosang from Orphan Europe of France was first approved in 1995. Panhematin (human hemin) from Ovation Pharmaceuticals is now being marketed in the USA. In Japan, there is no treatment for the disease even though at end 2002, it was estimated there were some 827 patients with porphyria, but the committee said that there are actually several times that number.
Heparin products recalled
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze